Evaxion Biotech A/S (EVAX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evaxion Biotech A/S (EVAX) trades at $4.80 with AI Score 66/100 (Buy). Evaxion Biotech A/S is a clinical-stage biotechnology company focused on developing AI-powered immunotherapies. Market cap: 30319546, Sector: Healthcare.
Last analyzed: Mar 15, 2026Evaxion Biotech A/S (EVAX) Healthcare & Pipeline Overview
Evaxion Biotech A/S is a clinical-stage biotechnology company leveraging artificial intelligence to develop novel immunotherapies for cancers and infectious diseases. Their pipeline includes multiple clinical-stage candidates, positioning them in the competitive immunotherapy market with a focus on AI-driven drug discovery and personalized medicine approaches within the healthcare sector.
Investment Thesis
Evaxion Biotech A/S presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's AI-driven approach to immunotherapy development offers the potential for novel and personalized treatments. Key value drivers include the successful progression of EVX-01 through its Phase IIb trial for metastatic melanoma, with results expected to influence future funding and partnership opportunities. Further catalysts include advancement of EVX-02 and EVX-03. Risks include clinical trial failures, regulatory hurdles, and the need for additional capital, which could dilute existing shareholders. The company's negative profit margin of -102.4% underscores its reliance on future clinical and commercial successes.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.03 billion, reflecting its small-cap status and potential for high growth or significant volatility.
- Negative P/E ratio of -3.53, indicating the company is currently not profitable and is investing heavily in research and development.
- Profit Margin of -102.4%, highlighting the company's significant expenses relative to its revenue, typical for clinical-stage biotech companies.
- Beta of 0.32, suggesting the stock is less volatile than the overall market.
- No dividend yield, consistent with growth-oriented biotech companies that reinvest earnings into research and development.
Competitors & Peers
Strengths
- Proprietary AI platform for drug discovery
- Clinical-stage pipeline of immunotherapy candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- High cash burn rate
Catalysts
- Upcoming: Phase IIb clinical trial results for EVX-01 in metastatic melanoma.
- Upcoming: Advancement of EVX-02 into later-stage clinical trials.
- Ongoing: Strategic partnerships and collaborations with larger pharmaceutical companies.
- Ongoing: Expansion of AI platform for new drug discovery.
Risks
- Potential: Clinical trial failures for EVX-01, EVX-02, or EVX-03.
- Potential: Regulatory hurdles and delays in obtaining marketing approvals.
- Ongoing: Competition from larger pharmaceutical companies with established immunotherapy platforms.
- Ongoing: Dependence on additional funding to support research and development activities.
- Potential: Intellectual property disputes or challenges to patent protection.
Growth Opportunities
- Expansion of EVX-01 into additional cancer indications: The success of EVX-01 in metastatic melanoma could pave the way for its application in other cancer types. The global market for cancer therapies is substantial, offering significant revenue potential if EVX-01 demonstrates efficacy across multiple indications. This expansion would require further clinical trials and regulatory approvals, with a timeline of 3-5 years.
- Advancement of EVX-02 and EVX-03 clinical programs: Progressing EVX-02 and EVX-03 through clinical trials represents a key growth opportunity. Positive data from these trials could attract partnerships with larger pharmaceutical companies and accelerate their development. The market for DNA-based immunotherapies is growing, driven by their potential for personalized cancer treatments. Timeline for significant revenue generation is 5-7 years.
- Development of novel vaccines for bacterial and viral diseases: Evaxion's preclinical programs, EVX-B1, EVX-B2, and EVX-V1, target bacterial and viral diseases, addressing a significant global health need. Successful development and commercialization of these vaccines could generate substantial revenue streams. The global vaccine market is projected to reach billions of dollars, with increasing demand for innovative vaccines. Timeline for market entry is 5-10 years.
- Strategic partnerships and collaborations: Collaborating with larger pharmaceutical companies or research institutions can provide Evaxion with access to additional funding, expertise, and resources. These partnerships can accelerate the development and commercialization of its product candidates. The biotechnology industry is characterized by collaborations, and successful partnerships are crucial for smaller companies like Evaxion. Ongoing.
- Leveraging AI platform for new drug discovery: Evaxion's AI platform can be used to identify and develop new drug candidates beyond its current pipeline. This platform offers a competitive advantage by enabling faster and more efficient drug discovery. The market for AI-driven drug discovery is growing rapidly, with increasing adoption of AI technologies in the pharmaceutical industry. Ongoing.
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Positive clinical trial results
- Increasing demand for personalized medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars
- Economic downturn
Competitive Advantages
- Proprietary AI platform for drug discovery.
- Clinical-stage pipeline of immunotherapy candidates.
- Expertise in DNA-based vaccine development.
About EVAX
Evaxion Biotech A/S, founded in 2008 and headquartered in Hørsholm, Denmark, is a clinical-stage biotechnology company dedicated to pioneering artificial intelligence-powered immunotherapies. The company focuses on addressing significant unmet needs in cancer, bacterial diseases, and viral infections. Evaxion's core strategy revolves around utilizing its proprietary AI platform to identify and develop novel drug candidates that can stimulate the body's immune system to fight disease. Their lead product candidates include EVX-01, a cancer immunotherapy currently in Phase IIb clinical trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy targeting various cancers. Additionally, Evaxion is advancing preclinical programs, including EVX-B1, EVX-B2, and EVX-V1, which are vaccines designed for the treatment of bacterial and viral diseases. Evaxion's commitment to innovation and its AI-driven approach distinguish it within the competitive biotechnology landscape, positioning the company to potentially deliver transformative therapies for a range of challenging diseases.
What They Do
- Develop artificial intelligence-powered immunotherapies.
- Focus on treatments for cancers, bacterial diseases, and viral infections.
- Advance EVX-01, a cancer immunotherapy, through Phase IIb clinical trials for metastatic melanoma.
- Develop EVX-02, a DNA-based cancer immunotherapy, currently in Phase IIa trial for adjuvant melanoma.
- Create EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
- Research EVX-B1, EVX-B2, and EVX-V1 vaccines in the pre-clinical stage for bacterial and viral diseases.
Business Model
- Develops proprietary AI platform for identifying novel drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for late-stage development and commercialization.
- Generates revenue through research grants, milestone payments, and royalties on marketed products.
Industry Context
Evaxion Biotech A/S operates within the rapidly evolving biotechnology industry, specifically in the immunotherapy and vaccine development space. The global immunotherapy market is projected to reach billions of dollars by 2026, driven by advancements in personalized medicine and AI-driven drug discovery. Evaxion's focus on AI-powered immunotherapies positions it to potentially capitalize on these trends. The competitive landscape includes companies like ANVS, BCAB, BTAI, CELU, and GBIO, as well as larger pharmaceutical companies with established immunotherapy platforms. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Key Customers
- Pharmaceutical companies seeking novel immunotherapy candidates.
- Patients with cancers, bacterial diseases, and viral infections.
- Healthcare providers administering Evaxion's therapies.
Financials
Chart & Info
Evaxion Biotech A/S (EVAX) stock price: $4.80 (+0.09, +1.91%)
Latest News
-
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
MT Newswires · Mar 25, 2026
-
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Yahoo! Finance: EVAX News · Mar 24, 2026
-
Notice to convene Evaxion's Annual General Meeting
globenewswire.com · Mar 19, 2026
-
Evaxion to present new data at AACR Annual Meeting
Yahoo! Finance: EVAX News · Mar 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVAX.
Price Targets
Consensus target: $10.00
MoonshotScore
What does this score mean?
The MoonshotScore rates EVAX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
Notice to convene Evaxion's Annual General Meeting
Evaxion to present new data at AACR Annual Meeting
Leadership: Andreas Holm Mattsson
CEO
Andreas Holm Mattsson serves as the CEO of Evaxion Biotech A/S. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Evaxion, he held leadership positions at various companies, focusing on strategic development, commercialization, and business operations. He has a proven track record in driving growth and innovation within the healthcare sector. His expertise spans across multiple therapeutic areas, including oncology and infectious diseases. He is responsible for managing 46 employees.
Track Record: Under Andreas Holm Mattsson's leadership, Evaxion Biotech A/S has focused on advancing its clinical-stage pipeline and leveraging its AI platform for drug discovery. Key milestones include the progression of EVX-01 into Phase IIb clinical trials and the expansion of its preclinical programs. He has also overseen strategic partnerships and collaborations aimed at accelerating the development and commercialization of Evaxion's product candidates.
Evaxion Biotech A/S ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. EVAX, as an ADR, allows U.S. investors to easily invest in Evaxion Biotech A/S without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, simplifying trading and reporting for U.S. investors.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About EVAX
What does Evaxion Biotech A/S do?
Evaxion Biotech A/S is a clinical-stage biotechnology company that leverages artificial intelligence to develop novel immunotherapies for cancers and infectious diseases. Their proprietary AI platform enables the identification of promising drug candidates, which are then advanced through preclinical and clinical development. The company's pipeline includes several clinical-stage candidates targeting metastatic melanoma and other cancers, as well as preclinical programs focused on bacterial and viral diseases. Evaxion aims to address unmet medical needs by creating personalized and effective immunotherapies.
What do analysts say about EVAX stock?
Analyst coverage of Evaxion Biotech A/S (EVAX) is limited, reflecting its small-cap status and early stage of development. Existing analyst reports focus on the potential of its AI-driven drug discovery platform and the clinical progress of its lead candidate, EVX-01. Key valuation metrics include potential peak sales for its product candidates and the probability of success in clinical trials. Growth considerations center on the company's ability to secure partnerships and funding to support its research and development efforts. Analyst opinions are subject to change based on clinical trial outcomes and regulatory developments.
What are the main risks for EVAX?
Evaxion Biotech A/S faces several significant risks inherent to the biotechnology industry. Clinical trial failures represent a major risk, as the success of its product candidates depends on positive data from clinical studies. Regulatory hurdles and delays in obtaining marketing approvals could also impede the company's progress. Competition from larger pharmaceutical companies with established immunotherapy platforms poses a threat. Additionally, Evaxion relies on securing additional funding to support its research and development activities, and any inability to raise capital could negatively impact its operations. Intellectual property disputes or challenges to patent protection also represent a risk.
What are the key factors to evaluate for EVAX?
Evaxion Biotech A/S (EVAX) currently holds an AI score of 66/100, indicating moderate score. Analysts target $10.00 (+108% from $4.80). Key strength: Proprietary AI platform for drug discovery. Primary risk to monitor: Potential: Clinical trial failures for EVX-01, EVX-02, or EVX-03.. This is not financial advice.
How frequently does EVAX data refresh on this page?
EVAX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EVAX's recent stock price performance?
Recent price movement in Evaxion Biotech A/S (EVAX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $10.00 implies 108% upside from here. Notable catalyst: Proprietary AI platform for drug discovery. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EVAX overvalued or undervalued right now?
Determining whether Evaxion Biotech A/S (EVAX) is overvalued or undervalued requires examining multiple metrics. Analysts target $10.00 (+108% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EVAX?
Before investing in Evaxion Biotech A/S (EVAX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on thorough research and consultation with a financial advisor.